Palmitoylethanolamide (PEA)

 

For clinical information about palmitoylethanolamide (PEA)  and formulations, please see:

Palmitoylethanolamide (PEA)

 

Availability

Palmitoylethanolamide (PEA) is available online. While there are multiple products available, the following two are presented for convenience.

 

 PEA is now available in U.S.:

  1. PEACure (liposomal and regular formulations)
  2. Vitalitus PEA (topical cream and regular formulation)

 

PEA is now available from the Netherlands as capsules or a topical cream.:

  1. PeaPure (standard formulations)
  2. PeaCream (topical cream)


Other brands now are available on the internet

 

Dosing

The dosing used in studies on PEA vary and there is no established dose. One recommendation is to start at 350-400mg 3 times/day and maintain this dose for 8-12 weeks to assess benefit. While there is little likelihood of any side effects, if they do occur reduce dose to 400mg twice a day and discontinue if PEA is not tolerated. Duration of use is not established. One recommendation would be to sustain the effective dose for 4-6 months then consider reducing maintenance dose and/or use of supplement holidays.

Disclaimer

I have no experience, first or second-hand, with these web sites or these products and I offer these links only as a convenience for patients to explore.

.

PeaCure Liposmal Formulation

 

peaCURE medical food 60 (vegetarian) capsules

 

palmitoylethanolamidepeaCURE medical food 90 (vegetarian) capsules

 

 

Vitalitus PEA 350mg #60

 

 

Vitalitus Soothamide (PEA 2% Topical Cream)

.

peaCURE (Liposomal)

 

Liposomal peaCURE is designed to combine the impressive benefits and safety of palmitoylethanolamide and the advanced liposomal delivery system. Liposomes ensure that the entire amount is delivered exactly where and when needed, without any loss due to enzymes or stomach acids. Tests have shown that liposomal delivery system greatly increases bioavailability and thus makes smaller amounts of PEA more effective.

 

Difference

Aside from the general benefits of the liposomal delivery system, taking 7.5 ml of Liposomal peaCURE is equal to taking 4 peaCURE capsules a day.

 

The improved delivery and absorption which comes from liposomes greatly improves bioavailability of palmitoylethanolamide (PEA) and makes it more effective than higher dosages of PEA administered via oral capsules.

 

Ingredients

3,2% PEA
11,2% Lecithine (Soy)
7,8% Glycerol
<1,5% Alcohol
0,2% Kalium Sorbaat
>77% Water

 Dosage

Regular dosage is 7,5 ml a day (equal to 4 capsules per day).

 

Storage

After opening, store in the refrigerator. Use before the end date marked on the packaging. Store cool and dry.

 

Important information

Not to be used by pregnant women.

Palmitoylethanolamide may help nutritionally address inflammation and chronic pain.

It should only be taken under medical supervision.

For more clinical information and information on formulations,

See Palmitoylethanolamide (PEA)

peaCURE

  1. Pharmaceuticals Grade Palmitoylethanolamide
  2. Medical food
  3. No side effects
  4. Size: 60 capsules & 90 capsules
  5. 400 mg per capsule
  6. Use: 3 times per day
  7. Made in Europe
  8. Guaranteed free of lactose, yeast, added sucrose, soybean, GMOs, animal products, artificial coloring, odors and flavors, gluten, preservatives, corn and gelatin

 

Important Information

Not to be used by pregnant women.

Palmitoylethanolamide may help nutritionally address inflammation and chronic pain.

It should only be taken under medical supervision.

For more clinical information and information on formulations,

See Palmitoylethanolamide (PEA)

 

 

PeaPure capsules

 

PeaPure cream

.

PeaPure® (Standard Formulation)

 

Ingredients

30 vegetarian capsules
Ingredients: palmitoylethanolamide, hydroxypropyl methylcellulose (capsule)
Each capsule contains 400 mg palmitoylethanolamide (PEA).

Product Description

Description of PeaPure® capsules

PeaPure® is a food supplement based on a natural and fatty-acid like compound.
The substance palmitoylethanolamide (PEA) is a physiologically active molecule that the body produces naturally. Patent on formulation pending.

What the user should know prior to ingestion:

There are no known significant side effects.

PeaPure® can be taken simultaneously with other medicine. In case of doubt, it is recommended to first consult your doctor or a pharmacist.

Use during pregnancy is NOT recommended.

PeaPure® does not contain sugar, yeast, allergens, sorbitol, magnesium stearate, povidone or other ingredients.

Dosage and administration

Administration: During or after the meal, swallow 1 capsule together with water, or sprinkle the content of the capsule on your food.

Dosage:
First 2 months:  1 capsule 3 times daily

Next 2 months: In case of a positive result,  1 capsule 2 times daily

After 4 months, you can consider the following:

Continue taking 2 times 1 capsule daily.

Reduce the ingestion to 1 times 1 capsule daily.

Stop the ingestion.

In case of regression, it is recommended to increase the dosage to 2 or 3 times 1 capsule daily. It is possible to continue taking PeaPure® in the correct dosage.
Do not exceed the recommended daily dosage.*

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

For more clinical information and information on formulations,

See Palmitoylethanolamide (PEA)

.

Palmitoylethanolamide (PEA) Overview

Palmitoylethanolamide (PEA), an endogenous fatty acid amide, is emerging as a new agent in the treatment of pain and inflammation. The compound was used many decades ago in other countries, but since the 1990s, interest has surged again. It is classified as a food for medical purposes or as a diet supplement in various countries of Europe.

 

PEA has shown effectiveness in many different preclinical animal studies for chronic and neuropathic pain, and most importantly effectiveness in reducing pain in various human clinical trials. Human studies demonstrate PEA to be effective for different types of pain, including nerve pain, inflammatory pain and visceral pain such as endometriosis and interstitial cystitis. Clinical benefits have been shown for fibromyalgia,  peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental pains, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, postherpetic neuralgia, and rectal and vaginal pains.

 

Probably related to the fact that PEA is endogenous (manufactured by the body) and a compound found in foods such as eggs and milk, no serious side effects or drug–drug interactions been identified.

 

For more clinical information and information on formulations,

See Palmitoylethanolamide (PEA)


References

  1. Palmitoylethanolamide4Pain.com

PEA – Availability

  1. PEACure
  2. PeaPure

 

Palmitoylethanolamide (PEA)

PEA – Overview

  1. Information for MDs and Pharmacists on Palmitoylethanolmide
  2. Chronic Pain in the Elderly – The Case for New Therapeutic Strategies – 2015
  3. Palmitoylethanolamide for the treatment of pain – pharmacokinetics, safety and efficacy
  4. Food-Derived Natural Compounds for Pain Relief in Neuropathic Pain – 2016
  5. Palmitoylethanolamide – A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold – 2013 
  6. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain – A Pooled Data Meta-analysis – 2016
  7. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. 2012 – PubMed – NCBI
  8. N-palmitoyl-ethanolamine – Biochemistry and new therapeutic opportunities – 2010

PEA – Anxiety and Depression

  1. Effects of palmitoylethanolamide and luteolin in an animal model of anxiety:depression. – PubMed – NCBI

PEA – Colds and Flu

  1. Palmitoylethanolamide – A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold – 2013

PEA – Pain Conditions/Diagnoses

PEA – Arthritis

  1. Degenerative Joint Diseases and Neuroinflammation – 2017
  2. A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models – 2017 

 

PEA – Ba
ck Pain

  1. Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome – 2017

PEA – Carpal Tunnel and Nerve Comeprssion Syndromes

  1. Use of palmitoylethanolamide in the entrapment neuropathy of the me… – PubMed – NCBI
  2. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes – efficacy and safety in sciatic pain and carpal tunnel syndrome – 2015
  3. The carpal tunnel syndrome in diabetes – Clinical and electrophysiological improvement after treatment with palmitoylethanolamide. – 2010
  4. Effect of a new formulation of micronized and ultramicronized N-palmitoylethanolamine in a tibia fracture mouse model of complex regional pain syndrom – 2017


PEA – CRPS (Chronic Regional Pain Syndrome)

  1. Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream – 2013
  2. Effect of a new formulation of micronized and ultramicronized N-palmitoylethanolamine in a tibia fracture mouse model of complex regional pain syndrom – 2017

 

PEA – Endometriosis

  1. Micronized palmitoylethanolamide:trans – polydatin treatment of endometriosis-related pain – A meta-analysis – 2017
  2. The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain – 2013
  3. Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)- transpolydatin in the treatment of chronic pelvic pain related to endometriosis – 2011

 

PEA – Fibromyalgia

  1. Palmitoylethanolamide in Fibromyalgia – Results from Prospective and Retrospective Observational Studies – 2015


PEA –Headaches (Migraine)

  1. PeaPure – Palmitoylethanolamide for Nerve Pain or Migraine

PEA – Multiple Sclerosis

  1. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokinesin Relapsing–Remitting Multiple Sclerosis – 2016


PEA – Proctodynia and Vulvodynia (Rectal and Vaginal Pain)

  1. Vulvodynia & proctodynia treated with topical baclofen 5 % & palmitoylethanolamide | Pain Management Specialist in San Diego & La Jolla


PEA – Pudendal Neuralgia

  1. Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to … – PubMed – NCBI

PEA – Pain Types/Mechanisms

 

PEA – Anti-inflammatory Mechanisms

  1. Palmitoylethanolamide “PEA” – Review of Anti-inflammatory, Analgesic, Neuroprotective Mechanisms
  2. Palmitoylethanolamide (PEA) – Boosting Its Anti-inflammatory Immune Response

PEA – Central Sensitivity,  Oxidative Stress and Pain

  1. Palmitoylethanolamide in CNS health and disease. – PubMed – NCBI
  2. Palmitoylethanolamide reduces
    pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice – 2015

PEA – Morphine Tolerance

  1. Delay of morphine tolerance by palmitoylethanolamide

PEA – Neuroinflammation, Glial Cells and Mast Cells

  1. Emerging targets in neuroinflammation-driven chronic pain – 2014
  2. Glia as a Link between Neuroinflammation and Neuropathic Pain – 2012
  3. Importance of glial activation in neuropathic pain. – PubMed – NCBI
  4. Mast cells, glia and neuroinflammation – partners in crime? – 2013
  5. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. – PubMed – NCBI
  6. Mast cell–glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide – 2012
  7. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity – involvement of the CB2 receptor – 2017
  8. Palmitoylethanolamide Increases after Focal Cerebral Ischemia and Potentiates Microglial Cell Motility – 2003
  9. N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution. – PubMed – NCBI

  

PEA – Neuropathic Pain

  1. Microglia in the spinal cord and neuropathic pain – 2016
  2. Can modulating inflammatory response be a good strategy to treat neuropathic pain? – PubMed – NCBI
  3. Chronic-idiopathic-axonal-neuropathy-and-pain–treated-with-PEA
  4. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. – PubMed – NCBI
  5. Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy – Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism
  6. Peroxisome proliferator-activated receptor agonists modulate neuropathic pain – 2014
  7. Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain
  8. Micronized Palmitoylethanolamide Reduces the Symptoms of Neuropathic Pain in Diabetic Patients
  9. Palmitoylethanolamide restores myelinated-fibre function in patient… – PubMed – NCBI
  10. delay-of-morphine-tolerance-by-palmitoylethanolamide-2015
  11. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes – efficacy and safety in sciatic pain and carpal tunnel syndrome – 2015
  12. Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome – 2017
  13. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. – PubMed – NCBI
  14. N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution. – PubMed – NCBI
  15. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain – A Pooled Data Meta-analysis – 2016
  16. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions – a case series – 2012
  17. Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain – 2014
  18. Comment on ‘‘Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain’’ – 2014
  19. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. – PubMed – NCBI

PEA – Visceral Pain, Endometriosis

  1. The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain – 2013
  2. Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)- transpolydatin in the treatment of chronic pelvic pain related to endometriosis – 2011

 

PEA – Products

PEA – Micronization Product Formulations

  1. A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury
  2. Micronization: a method of improving the bioavailability of poorly soluble drugs. – PubMed – NCBI
  3. Safety of micronized palmitoylethanolamide (microPEA) – lack of toxicity and genotoxic potential – 2017
  4. Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain – 2014
  5. Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain –
  6. study protocol for a series of N-of-1 randomized trials – 2015
  7. Micronized palmitoylethanolamide:trans – polydatin treatment of endometriosis-related pain – A meta-analysis – 2017

  

PEA –Topical

  1. Topical Analgesics – Critical Issues Related to Formulation and Concentration – 2016
  2. Topical analgesic creams and nociception in diabetic neuropathy – towards a rationale fundament – 2016

.

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online or at Accurate Clinic.

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

Accurate Supplement Prices

 

 

.